News Snapshot:
China National Biotec Group Co. (CNBG), a leading vaccine developer has sought authorisation to bring its COVID-19 candidate to the current market, Bloomberg has reported. The Bloomberg report cites Shi Shengyi, the vice general director of Sinopharm — CNBG’s parent company — as saying that an application in this regard was submitted to Chinese regulators on November 25. The application is likely to include data from the phase-3 clinical trials that were conducted at the Middle East and South America. CNBG, Sinopharm Group and China’s drug regulator, the National Medical Products Administration, didn’t immediately confirm that development. This would create...
